This Viewpoint argues safety and effectiveness are inseparable in US drug approval, that postmarket approaches to assess safety and effectiveness are insufficient, and that reducing the emphasis on effectiveness undermines autonomy.
No takes yet. Share an insight, caveat, or question.
Zettler et al. (2025) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: